A Practical Guide for Using Registry Data to Inform Decisions About the Cost Effectiveness of New Cancer Drugs: Lessons Learned from the PHAROS Registry
Crossref DOI link: https://doi.org/10.1007/s40273-015-0260-4
Published Online: 2015-02-03
Published Print: 2015-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Blommestein, Hedwig M.
Franken, Margreet G.
Uyl-de Groot, Carin A.
License valid from 2015-02-03